The V617F JAK2 mutation and the myeloproliferative disorders

Hematological Oncology

Volumn 23, Issue 3-4, 2005, Pages 91-93

  Percy, Melanie J ^a   McMullin, Mary Frances ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

ARMS PCR; JAK2; Mutation; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

CELL DNA; JANUS KINASE 2; PHENYLALANINE; PROTEIN TYROSINE KINASE; VALINE;

ALLELE; AMINO ACID SUBSTITUTION; CELL LINEAGE; CHROMOSOME 9; DNA SEQUENCE; ENZYME INHIBITION; GENE; GENE AMPLIFICATION; GENE LOCATION; GENE MUTATION; GRANULOCYTE; HEMATOLOGIC MALIGNANCY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; JAK2 GENE; JH2 DOMAIN; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; REVIEW; THROMBOCYTHEMIA;

ALLELES; AMINO ACID SUBSTITUTION; CHROMOSOMES, HUMAN, PAIR 9; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; HETEROZYGOTE; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; PHENYLALANINE; POINT MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; VALINE;

EID: 30344484239     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.761     Document Type: Review

References (19)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-375.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005; 3546: 1-5.
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7(4): 387-397.
5. Baxter EJ, Scott LM, Campbell PJ, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
6. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin progenitors in polycythemia vera. Exp Hematol 2004; 32: 179-187.
7. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30: 229-236.
8. Baxter JE, Scott LN, Campbell PJ, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
9. Prchal JF, Axelrad AA. Letter: bone marrow responses in polycythaemia vera. N Engl J Med 1974; 290: 1382.
10. Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively activated in some patient with polycythemia vera. Exp Hematol 2001; 29: 694-702.
11. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998; 338: 564-571.
12. Dai C, Chung IJ, Krantz SB. Increased erythropoiesis in polycythemia is associated with increased erythroid proliferation and increased phosphorylation of Akt/PKB. Exp Hematol 2005; 33: 152-158.
13. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-216.
14. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndrome. Blood 2005; 106: 1207-1209.
15. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788-22792.
16. Kravolics R, Teo S-S, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of JAK2. Blood 2005; E pub ahead of print.
17. Goerttler PS, Steimle C, Marz E, et al. The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood 2005; E pub ahead of print.
18. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakyocytic leukemia. Blood 2005; E pub ahead of print.
19. Levine RL, Loriaux M, Huntly BJP, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic leukemia. Blood 2005; E pub ahead of print.